Boston Scientific Corporation (BSX) recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The deal, originally announced in January this year, enables Boston Scientific’s entry into sacral neuromodulation (SNM), a high-growth adjacency for its Urology business.The company paid $71 cash per share to Axonics, representing an equity value of $3.7 billion and an enterprise ...

MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction."Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice presiden ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.08%. A quarter ago, it was expected that this medical technology company would post earnings of $0.08 per share when it actually produced earnings of $0.13, delivering a surprise of 62.50%.Over t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...

Exhibit 99.1 Axonics Reports Third Quarter 2024 Financial Results IRVINE, Calif. – November 7, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. "Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year," said Raymond W. Cohen, ...

Axonics, Inc. (AXNX) has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia.This cutting-edge device features a 20-year functional life and reduces recharge frequency to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15). Paired with intuitive remote control and enhanced MRI compatibility, the R20 builds on Axonics’ c ...

Axonics (AXNX) recently announced that a jury in the U.S. District Court for the Central District of California ruled unanimously in its favor in a patent infringement lawsuit filed by Medtronic (MDT) .The lawsuit, which started in 2019, focused on alleged patent violations concerning sacral neuromodulation (SNM) technology used to treat bladder and bowel dysfunction. The jury determined that Axonics did not infringe on any of the three patents in question, marking a critical win for AXNX.The patent dispute ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 62.50%. A quarter ago, it was expected that this medical technology company would post a loss of $0.05 per share when it actually produced a loss of $0.38, delivering a surprise of -660%.Over the last f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

Revenue Growth - Record net revenue of $114.6 million, a 23% increase year-over-year, driven by higher utilization and new accounts[2] - Sacral neuromodulation revenue reached $91.2 million, up 23% compared to the prior year period[2] - Bulkamid revenue grew to $23.4 million, a 25% increase year-over-year[2] - Net revenue for Q2 2024 increased to $114.565 million, up 23.3% from $92.894 million in Q2 2023[14] - Sacral neuromodulation revenue in the U.S. for Q2 2024 reached $89.076 million, up 23.4% from $72.205 million in Q2 2023[15] - Bulkamid revenue in the U.S. for Q2 2024 grew to $18.306 million, a 23.6% increase from $14.806 million in Q2 2023[15] Profitability and Margins - Gross margin expanded to 77.8%, up from 75.6% in the prior year period[2] - Gross profit for Q2 2024 rose to $89.143 million, a 27% increase from $70.190 million in Q2 2023[14] - Net income of $6.9 million, compared to a net loss of $7.3 million in the prior year period[2] - Net income for Q2 2024 improved to $6.899 million, compared to a net loss of $7.342 million in Q2 2023[14] - Comprehensive income for Q2 2024 was $7.365 million, a significant recovery from a comprehensive loss of $3.592 million in Q2 2023[14] Adjusted EBITDA - Adjusted EBITDA increased to $23.4 million, up from $18.4 million in the prior year period[2] - Adjusted EBITDA for Q2 2024 was $23.436 million, compared to $18.411 million in Q2 2023, reflecting a 27.3% increase[17] Cash and Assets - Cash, cash equivalents, short-term investments, and restricted cash totaled $362 million as of June 30, 2024[2] - Inventory increased to $105.4 million, up from $79.9 million in the prior year period[10] - Total current assets grew to $512.1 million, compared to $491.4 million in the prior year period[10] Liabilities - Total liabilities increased to $104.0 million, up from $82.4 million in the prior year period[11] Expenses - Research and development expenses for Q2 2024 increased to $12.792 million, up 42.9% from $8.949 million in Q2 2023[14] - Acquisition-related costs for Q2 2024 were $2.652 million, significantly higher than $602,000 in Q2 2023[14] - Stock-based compensation expense for Q2 2024 was $8.611 million, down from $11.204 million in Q2 2023[17]